Cambridge Investment Research Advisors, Inc. Crispr Therapeutics Ag Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 39,189 shares of CRSP stock, worth $1.42 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,189
Previous 34,275
14.34%
Holding current value
$1.42 Million
Previous $1.35 Million
1.11%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding CRSP
# of Institutions
479Shares Held
64.2MCall Options Held
2.15MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$369 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$220 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$138 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$101 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$92.2 Million1.16% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $2.83B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....